Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
Pfizer has increased its 2026 full-year guidance following strong third-quarter results driven by growth in cancer and migraine medications.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The company has raised its forecasts for both sales and profit, reporting a third-quarter earnings beat. According to data reported by marketscreener.com, Pfizer now expects its 2026 adjusted earnings per share (EPS) to fall within a range of $2.95 to $3.05. This projection sits slightly above the FactSet estimate of $2.96. Alongside these financial updates, the company has appointed a company veteran to serve as the new Chief Financial Officer, a move reported by CNBC. Extensive coverage from major financial outlets emphasizes the specific drivers behind this upward revision. Reuters and the Idaho Statesman highlight strong demand for Eliquis, a blood thinner drug, as well as the company's cancer drugs.
Endpoints News notes that sales in the cancer and migraine sectors are successfully offsetting a slide in Covid-related revenue. The Wall Street Journal describes this as momentum with new products, while Bloomberg characterizes the trend as an extension of a wider Big Pharma windfall. Quartz also confirms that the company surpassed earnings expectations during the third quarter. This shift in guidance is significant because it reflects Pfizer's transition away from its previous reliance on Covid-19 products. The coverage indicates that the growth of newer products is now central to the company's financial stability and confidence. By diversifying its revenue streams through oncology and neurology—specifically migraine treatments—the company is demonstrating a capacity to maintain profit growth despite the declining demand for pandemic-era medications.
The internal appointment of a veteran CFO suggests a strategic focus on continuity and experienced leadership during this period of product portfolio expansion. Looking ahead, analysts and investors will be monitoring whether the current demand for Eliquis and the cancer drug pipeline can sustain the revised EPS range of $2.95 to $3.05. Future reports will likely focus on whether the growth in these newer categories continues to neutralize the revenue loss from the Covid slide. The market will also be observing the first strategic moves made by the new CFO in managing the company's adjusted profit targets for the remainder of 2026 as the company seeks to maintain its current momentum.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (94% supported) Updated 13d ago.
Quick answers
What is Pfizer's projected EPS range for 2026?
Pfizer expects its 2026 adjusted EPS to be between $2.95 and $3.05.
Which products are driving Pfizer's growth?
Growth is being driven by strong demand for the blood thinner Eliquis, as well as cancer and migraine medications.
Who is joining the leadership team?
Pfizer has appointed a company veteran as its new Chief Financial Officer (CFO).
Coverage (12)
- Pfizer's Third-Quarter Results Reflect Confidence and Momentum Pfizer · 14d ago
- (PFE) Pfizer Expects 2026 Adjusted EPS Range $2.95 to $3.05, vs. FactSet Est of $2.96 marketscreener.com · 14d ago
- Pfizer lifts 2026 guidance as cancer, migraine sales offset Covid slide Endpoints News · 14d ago
- Pfizer raises 2026 forecasts on strong demand for Eliquis, cancer drugs Idaho Statesman · 14d ago
- Pfizer increases annual profit forecast amid solid demand for blood thinner drug Yahoo Finance · 14d ago
- Pfizer Raises Forecast on Momentum With New Products WSJ · 14d ago
- Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance Yahoo Finance · 14d ago
- Pfizer Raises 2026 Forecast, Extending Big Pharma Windfall Bloomberg · 14d ago
- Pfizer: Q3 Earnings Snapshot Yahoo Finance · 14d ago
- Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat Reuters · 14d ago
- Pfizer beat earnings expectations and raised its full-year sales and profit outlook Quartz · 14d ago
- Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO CNBC · 14d ago
Topics
Related trends
Here’s how much Medicare Part B premiums are rising in 2027
The Centers for Medicare & Medicaid Services announced that the standard Medicare Part B premium will increase by 3.2% for 2027.
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Disabled people in England ‘have to wait up to two years for wheelchairs’
England's NHS wheelchair services face systemic failure as disabled patients wait up to two years for essential mobility equipment.